Biological
GP 140 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
Studies by the year they started
3 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2017 | 1 |
Who runs them
Industry 3 · Other 0
Janssen Vaccines & Prevention B.V. (2) · Crucell Holland BV (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GP 140 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected AdultsCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT02935686Written as gp140 HIV Bivalent Vaccine
- Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) PreventionCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT02315703Written as gp140 DP Low-dose
- Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult VolunteersCompletedPhase 1Crucell Holland BVNCT02304185Written as gp140, 50 mcg